April 2010

TesoRx Pharma LLC. Founded by Dr. TR Thirucote, Dr. Guru Betageri and Will Robberts

Company proceeds to close initial private funding round and concludes in-licensing of platform technology from Western University of Health Sciences used to develop TSX-002 (oral Testosterone Replacement Therapy).

Guru, Will and TR

Guru, Will and TR


November 2012

After successful Phase 1 study of TSX-002, TesoRx commences Phase 2 Clinical Study in male subjects

Study concludes that product is safe, well tolerated and increases Testosterone levels in all subjects.

Photo by kupicoo/iStock / Getty Images

August 2013

TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug


August 2014

TesoRx closes Series B Financing of $10Million and appoints Dr. Michael Oefelein as its new Chief Medical Officer

Company also has a new patents granted that significantly strengthens its patent estate.


October 2014

First ex-USA licensing transaction with Aspen Pharmacare Holdings Limited for $100Million+

In addition to an upfront investment of $15Million, Aspen will be responsible for developing and commercializing TesoRx's testosterone treatment in a number of international territories. TesoRx retained the full rights to the product for the US, Europe, Japan, China, India and the Middle East.

Territories included were Latin America and Russia CIS

April 2015

Official Opening of the TesoRx Centre of Excellence at Western University


The ethos behind the Centre of Excellence is to leverage the scientific expertise of the university in collaboration with TesoRx to develop a portfolio of products that will advance innovative medical therapies which can be brought to market.


December 2015

TesoRx adds a novel new bladder cancer therapy and a testosterone treatment for boys with Constitutional Delay in Growth in Puberty (CDGP) to its product pipeline

Both new therapies have the potential of being best-in-class treatments and were spawned from the same platform technology originally licensed from WUHS. The CDGP treatment utilizes TSX-002's formulation and is targeting an orphan indication approval. TesoRx is replacing the TSX-002 formulation targeting hypogonadism in men with a next generation modified Testosterone treatment leveraging its platform technology that will be known as THG-1001.